Puma Biotechnology

Historical price data

Puma Biotechnology is a U.S.-based, commercial-stage oncology company with a proven strategy of in-licensing and developing targeted cancer therapies. Its flagship product, NERLYNX, generates revenue for the extended adjuvant treatment of HER2-positive early breast cancer. The company is advancing alisertib, an Aurora A kinase inhibitor, in pivotal trials for small cell lung cancer and metastatic breast cancer, aiming to diversify its revenue base. Puma's inclusion in the NASDAQ Biotechnology Index underscores its transition to a sustainable commercial entity.

Puma does not have a proprietary discovery platform; its core operational platform is a targeted in-licensing and development model focused on acquiring global rights to clinical-stage oncology assets with validated mechanisms of action and derisking them through late-stage development and commercialization.

NERLYNX competes in a dynamic HER2+ breast cancer market increasingly dominated by potent antibody-drug conjugates like Enhertu. Alisertib, if approved, would enter the crowded post-CDK4/6 inhibitor space in breast cancer and the niche late-line SCLC market, where its primary differentiation would be oral administration versus intravenous competitors like lurbinectedin.